Find a Provider

Xiaowei Xu, MD, PhD

Xiaowei Xu, MD, PhD Physician

Associate Professor of Dermatology
Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania

Languages spoken:

  • Chinese

Dr. Xu is a Penn Medicine employed physician.

Clinical Specialties

Specialties:

  • Pathology and Laboratory Medicine

Programs & Services:

  • Cancer
    • Merkel Cell Carcinoma
    • Skin Cancer
  • Pathology and Laboratory Medicine
    • Anatomic Pathology
    • Immunobiology and Experimental Pathology

Board Certification:

  • Dermatology - Dermatopathology, 2002
  • Pathology - Anatomic and Clinical Pathology, 2001

Conditions & Treatments:

  • Cancer Screening and Diagnostics
  • Melanoma
  • Non-Melanoma Skin Cancer
  • Skin Cancer

Clinical Interests

Pigmented lesion, vasculitis, dermatopathology

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Shanghai Medical University
Fellowship: Wake Forest Baptist Medical Center
Residency: Hospital of the University of Pennsylvania
Fellowship: Massachusetts General Hospital

Memberships

American Cancer Society, National International Society of Stem Cell Research, International Melanoma Research Foundation, National NCI review, Targeted Radionuclide Therapy, National NIH study section (RPRB-B (O1)), National NIH Study section, special emphasis panel (SEP-9), National Scottish Chief Scientist Office, International Society for Melanoma Research, National

Affiliation

Dr. Xu is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Research Interests:

Skin stem cells and melanoma

Selected Publications:

Yang R, Jiang M, Kumar SM, Xu T, Wang F, Xiang L, Xu X: Generation of melanocytes from Induced pluripotent stem cells J Invest Dermatol 131 (12): 2458-66,2011.

Yang R, Xu X: Isolation of neural crest stem cells from human hair follicles J Vis Exp 74 : 2013 doi: 10.3791/3194..

Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, et al: A Phase II, Open Label, Single-arm Trial of Imatinib Mesylate in Patients with Metastatic Melanoma Harboring c-Kit Mutation or Amplification J Clin Onco 29 (21): 2904-9,2011.

Yun SJ, Gimotty PA, Hwang WT, Dawson P, Van Belle P, Elder DE, Elenitsas R, Schuchter L, Guerry D, Xu X: High Lymphatic Vessel Density and Lymphatic Invasion Underlie the Adverse Prognostic Effect of Radial Growth Phase Regression in Melanoma Am J Surg Path 35 (3): 235-42,2011.

Yu H, Kumar SM, Kossenkov AV, Showe L, Xu X: Stem Cells with Neural Crest Characteristics Derived from the Bulge Region of Cultured Human Hair Follicles J Invest Dermatol 130 (5): 1227-36,2010.

Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton B, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KYJ, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D’Andrea K, Koehler A, Stumm M, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K: Clinical efficacy of a RAF inhibitor requires comprehensive ERK pathway inhibition in BRAF-mutant melanoma Nature 467 (7315): 596-9,2010.

Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis1 M, Cipolla1 AK, Wubenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker1 AE, Letrero R, Pushparajan A, Hayden JE, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M: Acquired resistance to BRAF inhibitors mediated by an A/B/C RAF kinase switch in melanoma can be overcome by co-targeting MEK and IGF-1R/PI3K Cancer Cell 18 (6): 683-95,2010.

Li, L., Fulunaga-Kalabis, M., Yu, H., Xu, X., Kong, J., Lee, J.T. Herlyn, M.:: Melanocyte stem cells can be isolated from the human dermis. J Cell Sci 123 (6): 853-60,2010.

Zhang G, Zhang H, Wang Q, Lal P, Carroll A, de la Llera-Moya M, Xu X, Greene MI.: Suppression of human prostate tumor growth by a prostate-specific monoclonal antibody F77 targeting a unique cell surface marker Proc Natl Acad Sci U S A 107 (2): 732-7,2010.

Yu H., Fang D., Kumar SM., Li L., Nguyen TK., Acs G., Herlyn M., Xu X.: Isolation of a novel population of multipotent adult stem cells from human hair follicles American Journal of Pathology 168 (6): 1879-88,2006.

Academic Contact Info

Hospital of University of Pennsylvania
Dept. of Pathology and Laboratory Medicine
6 Founders Pavilion

Philadelphia, PA 19104-4283
Phone: (215) 662-6503
Fax: (215) 349-5910

Related Links